K Number
K140348
Device Name
INTERBODY CAGE
Manufacturer
Date Cleared
2015-04-23

(436 days)

Product Code
Regulation Number
888.3080
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The Interbody Cage is indicated for use with autogenous bone graft in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. These DDD patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved levels. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment. These devices are intended for intervertebral body fusion, and are intended to be used with supplemental fixation instrumentation which has been cleared by the FDA for use in the lumbar spine.
Device Description
The Interbody Cage is offered in a variety of heights, widths, and lengths. The implants are manufactured from medical grade polyetheretherketone (PEEK) or titanium alloy. The devices are intended to be implanted either one device per level when used in the ALIF, Banana, or Lateral styles, and one or two devices per level when used in the PLIF/TLIF style. Tantalum pins are embedded in the PEEK versions of the implants to help allow for radiographic visualization.
More Information

No
The document describes a passive implant (interbody cage) and does not mention any computational or analytical capabilities, let alone AI/ML. The "Mentions AI, DNN, or ML" section explicitly states "Not Found".

Yes
The device, an Interbody Cage, is used in patients with degenerative disc disease for intervertebral body fusion to address discogenic back pain, which is a therapeutic intervention.

No

Explanation: The device is an intervertebral body fusion device used to treat degenerative disc disease, not to diagnose it. Its purpose is treatment and stabilization, not diagnostic imaging or analysis.

No

The device description clearly states the device is an implantable interbody cage made from PEEK or titanium alloy, which are physical materials, not software.

Based on the provided information, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • IVDs are used to examine specimens from the human body. The description clearly states the Interbody Cage is an implantable device intended for surgical use within the lumbar spine (L2 to S1). It is a physical device implanted into the body, not a test performed on a sample taken from the body.
  • The intended use is for surgical fusion. The purpose of the device is to facilitate the fusion of vertebrae in patients with degenerative disc disease. This is a therapeutic intervention, not a diagnostic test.
  • The device description details materials and physical characteristics. The description focuses on the materials (PEEK, titanium), dimensions, and styles of the implant, which are relevant to a surgical device, not a diagnostic test.
  • Radiographic studies are mentioned as part of the patient evaluation, not as the output of the device itself. The radiographic studies are used to confirm the diagnosis of degenerative disc disease and assess the patient's condition, not as a result generated by the Interbody Cage.

In summary, the Interbody Cage is a surgical implant used for spinal fusion, which falls under the category of medical devices, but not In Vitro Diagnostic devices.

N/A

Intended Use / Indications for Use

The Interbody Cage is indicated for use with autogenous bone graft in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. These DDD patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved levels. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment. These devices are intended for intervertebral body fusion, and are intended to be used with supplemental fixation instrumentation which has been cleared by the FDA for use in the lumbar spine.

Product codes

MAX

Device Description

The Interbody Cage is offered in a variety of heights, widths, and lengths. The implants are manufactured from medical grade polyetheretherketone (PEEK) or titanium alloy. The devices are intended to be implanted either one device per level when used in the ALIF, Banana, or Lateral styles, and one or two devices per level when used in the PLIF/TLIF style. Tantalum pins are embedded in the PEEK versions of the implants to help allow for radiographic visualization.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

L2 to S1 (lumbar spine)

Indicated Patient Age Range

skeletally mature

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Additional testing (compression) per ASTFM F2077 verified that the addition of new materials did not introduce a new worst-case. Therefore, the subject Interbody Cage is substatially equivalent to its predicates.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

K113478, K083714, K090425

Reference Device(s)

K133126, K132738, K123969, K133340

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 888.3080 Intervertebral body fusion device.

(a)
Identification. An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.(b)
Classification. (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.

0

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circle with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol that resembles a stylized caduceus, with three human profiles facing to the right.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

April 23, 2015

Eisertech. LLC Mr. Lukas Eisermann Chief Executive Officer 1133 Columbia Street, Suite 107 San Diego, California, 92101

Re: K140348

Trade/Device Name: Interbody Cage Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral body fusion device Regulatory Class: Class II Product Code: MAX Dated: March 25, 2015 Received: March 27, 2015

Dear Mr. Eisermann:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

1

Page 2 - Mr. Lukas Eisermann

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely vours.

Lori A. Wiggins -S

for

Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

2

Indications for Use

510(k) Number (if known) K140348

Device Name Interbody Cage

Indications for Use (Describe)

The Interbody Cage is indicated for use with autogenous bone graft in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. These DDD patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved levels. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment. These devices are intended for intervertebral body fusion, and are intended to be used with supplemental fixation instrumentation which has been cleared by the FDA for use in the lumbar spine.

Type of Use (Select one or both, as applicable)
☑ Prescription Use (Part 21 CFR 801 Subpart D)□ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

3

510(k) Summary:

Date:April 21, 2015
Company:Eisertech, LLC
1133 Columbia Street
Suite 107
San Diego, California 92101
Contact:Lukas Eisermann
lukas@eisertech.com
888-262-2817x101

Type of 510(k) submission: Traditional

Trade Name:Interbody Cage
Common Name:Intervertebral FusionDevice with Bone Graft,
Lumbar
Classification Name:Orthosis, spinal intervertebral fusion
Regulation Number:21 CFR 888.3080
Device Classification:Class II
Product Code:MAX

Purpose of the Submission

The purpose of this special 510(k) is to gain clearance for additional implant sizes and material options.

Description of device

The Interbody Cage is offered in a variety of heights, widths, and lengths. The implants are manufactured from medical grade polyetheretherketone (PEEK) or titanium alloy. The devices are intended to be implanted either one device per level when used in the ALIF, Banana, or Lateral styles, and one or two devices per level when used in the PLIF/TLIF style.

Tantalum pins are embedded in the PEEK versions of the implants to help allow for radiographic visualization.

InX]WUqcbqZffI se

The Interbody Cage is indicated for use with autogenous bone graft in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to

4

S1. These DDD patients may also have up to Grade I spondvlolisthesis or retrolisthesis at the involved levels. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment. These devices are intended for intervertebral body fusion, and are intended to be used with supplemental fixation instrumentation which as been cleared by the FDA for use in the lumbar spine.

Materials

The devices are manufactured either from medical grade PEEK (ASTM F2026) with tantalum radiographic markers (ASTM F560), or from titanium alloy (ASTM F136). The specific grades of PEEK used may be either Zeniva ZA-500 (Solvay) or Vestakeep 4iR (Evonik).

Predicate Devices

Primary Predicate:

Eisertech, LLC PLIF Cage (K113478)

Additional Predicates:

Titan Spine Endoskeleton (K083714) Alphatec GLIF Cage (K090425)

Reference Predicates:

K7, LLC - K133126 - Lumbar Cages Cogent Spine - K132738 - Lumbar Cage DiFusion - K123969 - ALIF Cage SpineWorks - K133340 - ALIF Cage

Technological Characteristics

The Interbody Cage geometry is similar to that cleared in K113478. The worstcase size testing submitted as part of K113478 applies to all devices that are part of this current submission.

The main material of construction is either PEEK (ASTM F2026) or titanium allov (ASTM F136). When used, the PEEK may be either Zeniva ZA-500 supplied by Solvay Advanced Polymers, which is one of the materials approved in K113478, or Vestakeep i4R, supplied by Evonik, Inc, which is the new material option being requested.

Performance Data

The additional materials and sizes do not alter the performance of the device. The additional PEEK option is equivalent in mechanical properties. The devices

5

made from titanium alloy are substantially stronger than those made from PEEK. All additional sizes are larger in bearing footprint than the worst-case size tested for K113478. Additional testing (compression) per ASTFM F2077 verified that the addition of new materials did not introduce a new worst-case. Therefore, the subject Interbody Cage is substatially equivalent to its predicates.